. 2015 Oct 31;10:221. doi: 10.1186/s13014-015-0523-4

Table 5.

Significantly associated clinical characteristics

Authors	LF	DF	LMC	OS
Iwai et al. [19]	Dose < 18Gy	N/A	Infratentorial location	N/A
Jagannathan et al. [27]	Greater treated volume	N/A	N/A	Systemic progression
Karlovits et al. [31]	N/A	N/A	N/A	>1 intracranial metastasis
Karlovits et al. [31]	N/A	N/A	N/A	Extracranial disease
Jensen et al. [15]	Preop diameter > 3 cm	Dose <35Gy	N/A	N/A
Rwigema et al. [20]	Greater PTV	N/A	N/A	Age
Rwigema et al. [20]	Greater PTV	N/A	N/A	RPA score
Choi et al. [21]	N/A	Melanoma histology	N/A	KPS Preop diameter
Ogiwara et al. [33]	N/A	N/A	N/A	Extracranial metastases
Prabhu et al. [22]	Larger PTV volume	N/A	N/A	N/A
Prabhu et al. [22]	Marginal dose <18 Gy	N/A	N/A	N/A
Brennan et al. [34]	NSCLC histology	Infratentorial location	N/A	N/A
	Preop diameter > 3 cm
	Dural/ pial involvement
Hartford et al. [35]	Preop diameter ≥ 2 cm	Preop diameter ≥ 2 cm	N/A	GPA ≤1
Ojerholm et al. [18]	Preop diameter ≥ 3 cm	N/A	Breast histology	New diagnosis or untreated primary
Ojerholm et al. [18]	Preop diameter ≥ 3 cm	N/A	Infratentorial location	New diagnosis or untreated primary
Ling et al. [25]	N/A	Uncontrolled systemic disease	N/A	Increasing no. metastases
		Melanoma histology		Uncontrolled systemic disease
		Increasing no. brain metastases		Uncontrolled systemic disease
Present study	N/A	Synchronous metastases	N/A	Male gender

LF local failure, N/A not applicable, PTV planning treatment volume, Preop preoperative, LMC leptomeningeal carcinomatosis, CK Cyberknife, OS overall survival, RPA recursive partitioning analysis, KPS Karnofsky performance status, GPA graded prognostic assessment, no. number